NCT07157254View on ClinicalTrials.gov

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2030

Conditions

Angelman Syndrome

Interventions

OTHER

No intervention

During the no treatment period participants do not receive any study drug

DRUG

GTX-102

antisense oligonucleotide

Trial Locations (1)

27278

RECRUITING

Rare Disease Research, Hillsborough

All Listed Sponsors

lead

Ultragenyx Pharmaceutical Inc

INDUSTRY

NCT07157254 - A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) | Biotech Hunter | Biotech Hunter